Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA) have jointly released a statement expressing concern over current HIV drug pricing and have also recommended improved access to effective HIV antiretrovirals both in the US and abroad.
Subscribe to our email newsletter
The organizations have called upon pharmaceutical companies to fix antiretrovirals prices at an affordable level for the HIV population and have also requested them to participate in programs like HarborPath as well as to work with US policymakers, public and private insurers to reduce restrictions on accessibility to HIV drugs.
They are also planning to share the recommendations with insurers and the Centers for Medicare and Medicaid Services (CMS).
HIVMA board of directors chair Michael Horberg said, "Reliable access to HIV medications is imperative for viral suppression and effective management of HIV infection, not only to improve the patient’s health but also to help prevent the spread of the disease."
AAHIVM board of directors chair Donna Sweet said if the full range of treatment options is not included in the drug formularies and costs aren’t kept down for third-party payers and individuals, the full benefit to HIV patients through the Patient Protection and Affordable Care Act (ACA) will not be achieved.
ACA is an act that offers an opportunity to increase access to HIV treatment and care.
AAHIVM and HIVMA are HIV care providers in the US.